Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
31,523,534
-
Total 13F shares
-
1,292,326
-
Share change
-
+54,256
-
Total reported value
-
$6,949,376
-
Put/Call ratio
-
48%
-
Price per share
-
$5.36
-
Number of holders
-
19
-
Value change
-
+$205,270
-
Number of buys
-
6
-
Number of sells
-
12
Institutional Holders of ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) as of Q4 2021
As of 31 Dec 2021,
ImmunoPrecise Antibodies Ltd. - Common Shares, no par value (IPA) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,292,326 shares.
The largest 10 holders included
INGALLS & SNYDER LLC, BANK OF MONTREAL /CAN/, MARSHALL WACE, LLP, Ikarian Capital, LLC, CREDIT SUISSE AG/, CITADEL ADVISORS LLC, Federation des caisses Desjardins du Quebec, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Gradient Capital Advisors, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
20
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.